At around 13:00 today, the 2026 national basic medical insurance drug catalogue negotiations and commercial insurance innovative drug catalogue price negotiations began on the afternoon of the 3rd day. The reporter observed on the scene that Columbite, BeiGene, Roche, AstraZeneca, Hengrui Pharmaceuticals, Daiichi Sankyo, Novartis, Pierre Faber, Sanofi, Bristol-Myers Squibb, Pfizer and other domestic and foreign companies entered the negotiations, and about 20 companies negotiated.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.